Nabriva Therapeutics PLC (NBRVF): BRIEF-Sinovant Sciences And Nabriva Ther...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	18
Posts	1646
Boards Moderated	0
Alias Born	06/26/2014

John-Knee

Re: None

Tuesday, 05/25/2021 6:58:39 PM

Tuesday, May 25, 2021 6:58:39 PM

BRIEF-Sinovant Sciences And Nabriva Therapeutics Announce Positive Topline Results From Phase 3 Trial Of Lefamulin In Chinese Adults With Community Acquired Bacterial Pneumonia (Cabp)
2021-05-25 06:53:41 PM ET (Reuters)

May 25 (Reuters) - Nabriva Therapeutics PLC:

* SINOVANT SCIENCES AND NABRIVA THERAPEUTICS ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF LEFAMULIN IN CHINESE ADULTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP)

* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS GENERALLY SAFE AND WELL-TOLERATED IN CHINESE ADULTS

* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS SHOWN TO BE NON-INFERIOR TO MOXIFLOXACIN

* NABRIVA THERAPEUTICS PLC - GREATER CHINESE RIGHTS TO LEFAMULIN WILL BE HELD BY SUMITOMO PHARMACEUTICALS (SUZHOU) CO., LTD., Source text for Eikon: Further company coverage:

I use both Fundamental and Technical Analysis.
Opinions posted by me are just that, my opinion.
Buy/sell any type of financial security is the sole
decision of the individual. Make your own sound
judgement or consult a professional licensed
advisor.